Profile of:

Antoni Chan

Antoni Chan is Consultant Rheumatologist and Clinical Lead at the University Department of Rheumatology at the Royal Berkshire NHS Foundation Trust. He did his medical undergraduate training at the University of Aberdeen, UK and postgraduate training in Oxford, UK. He completed his doctorate (PhD) in immunology in Oxford under the supervision of Professors Paul Bowness and Andrew McMichael. His PhD was on the role and function of Natural Killer (NK) cells and receptors in Spondyloarthritis. He leads the Spondyloarthritis (Axial SpA and Psoriatic Arthritis) service in his Trust. His interest include referral pathways in Axial Spondyloarthritis and the use of digital healthcare technologies to improve patient care. He is the Trust and Berkshire West Integrated Care Partnership clinical lead for Outpatient Transformation. In 2017, he set up the Berkshire West Integrated Pain Assessment and Spinal Service which was recognised by the British Society for Rheumatology with a Best Practice Award. His team was awarded the National Axial Spondyloarthritis Society (NASS) Aspiring to Excellence Award in 2019. In 2018 he received the Patient Choice Award for Best Care by a Rheumatologist from the NASS. He has presented in Parliament to the All-Party Parliamentary Group (APPG) on improving standards of care in Spondyloarthritis. He was elected as Trustee and Member of the Medical Advisory Board of NASS in 2020. He is a member of the Research and Registers Committee of the British Society for Rheumatology (BSR). He is Primary Investigator (PI) for numerous clinical trials in his department. In addition to his clinical, research and charity work, he also lectures and teaches at the Henley Business School where he is a Visiting Fellow at the University of Reading, UK. He presents regularly to national and international audiences on topics in Axial Spondyloarthritis. His work to reduce delays to diagnosis in axSpA was recognised by NASS and he was awarded the inaugural Gold Changemaker Award at the Houses of Parliament, UK in 2023. Follow on Twitter @synovialjoints

Full name: Antoni Chan

Current country: United Kingdom

Membership level: Full

Type of membership: Member

Number of publications: 25

Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebocontrolled, phase 2 trial (2024)

Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel (2024)

Successful Screening of Undiagnosed Psoriatic Arthritis in Primary Care Utilising Digital Interventions Within a Quality Improvement Programme (2024)

Improving triaging from primary care into secondary care using heterogeneous data-driven hybrid machine learning (2023)

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope (2023)

A concept for digital transformation for improved patient care in the UK (2023)

Remote monitoring in rheumatology: seeing the right patient at the right time (2023)

The Royal Berkshire NHS Foundation Trust outpatient services transformation programme to improve quality and effectiveness of patient care (2022)

Ankylosing Spondylitis Best Practice (2021)

Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis (2021)

Tele clinics in rheumatology introduced during the first lockdown phase of the COVID-19 pandemic of 2020 (2020)

Virtual or Face to Face in the Post COVID-19 world (2020)

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study (2020)

Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives (2020)

Myopericarditis and myositis in a patient with COVID-19: a case report (2020)

Real world experience of apremilast in treating psoriatic arthritis patients with comorbidities. (2019)

Implementing and delivering a successful biosimilar switch programme – the Berkshire West experience (2019)

The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index (2019)

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis (2016)

KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis (2013)

Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis (2011)

Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cells (2008)

Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide (2007)

CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts (2007)

Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis (2005)